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Clinical and Genetic Features of Choroideraemia in Childhood. 
1. Objective or Purpose: To review the functional and anatomical 
characteristics of choroideraemia in the paediatric population, aiming to 
describing the earliest features of disease, and identify biomarkers 
useful for monitoring disease progression. 
2. Design: Retrospective, case series. 
3. Subjects, Participants, and/or Controls: Children diagnosed with 
choroideraemia at a single institution.  
4. Methods, Intervention, or Testing: Subjects were identified using an 
electronic patient record system. Case notes and retinal imaging (colour 
fundus photography (CFP), spectral domain optical coherence tomography 
(SD-OCT) and fundus autofluorescence (FAF)) were then reviewed. The 
results of genetic testing were also recorded. 
5. Main Outcome Measures: Presenting symptoms, visual acuity, fundus 
changes (CFP, SD-OCT, FAF) and CHM sequencing results. 
6. Results: 29 patients were identified with a mean age at referral of 9 
years (range 3-16).  CHM mutations were identified in 15/19 patients 
tested. Nyctalopia was the predominant symptom (66%). 5/29 patients were 
asymptomatic at presentation. At the final follow up visit (mean age 16, 
range 7-26) the majority maintained excellent visual acuity (mean 0.98 
+/- 0.13 decimalized Snellen acuity). The first sign of retinopathy was 
widespread pigment clumping at the level of the retinal pigment 
epithelium (RPE). This later evolved to chorioretinal atrophy, most 
marked in the mid-peripheral retina. Peripapillary atrophy was also an 
early feature, and progressive in nature. Three different zones of FAF 
change were visible. Persistence of the inner retinal layers, detected by 
SD-OCT, was visible at presentation in 15/27 patients. Subfoveal 
choroidal thickness decreased with age whilst central retinal thickness 
increased over a similar interval. Four patients in whom visual acuity 
decreased over the follow-up period recorded a reduction in central 
retinal thickness. 
7. Conclusions:  Progressive structural changes occur at a time when 
central visual function is maintained. Pigmentary changes at the level of 
the RPE occur early in the disease course. Peripapillary chorioretinal 
atrophy, central retinal thickness and subfoveal choroidal thickness are 
likely to be valuable in monitoring disease progression, and should be 
considered as potential biomarkers in future therapeutic trials.  
 
 
 
 
 
 1 
Point-by-point response to reviewers’ comments. 
 
Dear Editors, 
 
Thank you very much for sending our manuscript for external review.  
 
As recommended, please find below a point-by-point response to the 
comments provided. 
 
Many thanks for considering this revised version for publication. 
 
Kind Regards 
Kamron 
 
Mr Kamron Khan  MB BChir MA PhD FRCOphth 
Honorary Consultant Ophthalmologist  
Moorfields Eye Hospital, London and St. James’s Hospital, Leeds 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Point-by-point response
 2 
 
 
Comment from Reviewer 1  Response Changes made to text 
Was foveal thickening due 
to the retained inner 
retinal layers or was the 
ONL also thickened? 
Thank you. We have 
tried to address this in 
the text: “Persistence of 
the inner retinal layers 
was observed in 15/27 
cases” (line 201). A 
further sentence 
confirming absence of 
ONL oedema has been 
added. 
Text added for clarity, 
please see lines 203-204 
Do the authors have visual 
field, microperimetry, or 
electrophysiology data? It 
would be a shame not to 
include these data if 
available. 
 
Unfortunately these 
investigations are not 
routinely performed in 
an NHS clinic. 
Consequently these 
data are not available  
 
We agree that this 
information would be 
useful and add to our 
current knowledge of 
CHM and we aim to 
collect these data as 
part of a prospective 
natural history study. 
 
Comment from Reviewer 2  Response Changes made to text 
The authors should state 
the time period (years and 
months) for the patient 
visits that were part of this 
retrospective study. 
 
 
Thank you. This 
information is included 
in the Table. 
Changes made to the 
follow-up column in the 
Table. Time is recorded in 
years and decimalised 
months. 
…it is recommended that 
the authors include 
wording to the effect that 
the chart review returned 
"Twenty-nine patients (28 
pedigrees) were identified 
where the initial visit was 
under the age of 17 years." 
Thank you. We agree. Text has been added for 
clarity, please see lines 
127-8. 
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Other reports have 
described patients with 
chroideremia in later 
stages of the disease 
where peripapillary 
sparing of the 
RPE/choriocapillaris was 
evident. Was this seen 
with any of the children as 
they got older? Was it 
observed in older affected 
family members of any of 
the pedigrees? 
Thank you. We have 
reviewed the images of 
patients in this cohort, 
and where available 
their affected or carrier 
relatives. Peripapillary 
sparing was not 
observed, even in the 
most hyperopic 
individuals. 
 
The authors should 
consider referencing the 
recent report of 
occurrence of CNV with 
subretinal fibrosis 
presenting in a 13 year-old 
male with familial 
choroideremia. Palejwala 
NV, et al. Choroideremia 
associated with choroidal 
neovascularization treated 
with intravitreal 
bevacizumab. Clinical 
Ophthalmology 2014 
8:1675-1679. 
Thank you. We agree. 
This is similar to 
patient 10 in our series. 
Text has been added for 
clarity, lines 341-5 and 
reference 18. 
…the authors should 
consider making a table 
that emphasizes the 
earliest symptoms and 
findings of choroideremia 
and the youngest ages that 
they have observed these 
features.  
Thank you. Findings of 
widespread pigmentary 
change, persistence of 
the inner retinal layers, 
and progressive sub-
foveal choroidal 
thinning were visible as 
soon as retinal imaging 
was possible. One 5 
year old displays all 
these features. In order 
to determine the exact 
order in which these 
occur we plan to 
prospectively 
Please see lines 357-9. 
Rather than include a 
table stating “age 5” in all 
columns we have inserted 
a sentence noting that 
these signs were evident 
in the youngest patients in 
our cohort. 
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investigate this. 
 
 
 
 
 
 
Précis 
This work describes in detail the clinical features of choroideraemia in childhood.  We present novel 
features of disease and propose biomarkers which will be useful in monitoring disease progression and 
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Clinical and Genetic Features of Choroideraemia in Childhood. 31 
1. Objective or Purpose: To review the functional and anatomical characteristics of 32 
choroideraemia in the paediatric population, aiming to describing the earliest 33 
features of disease, and identify biomarkers useful for monitoring disease 34 
progression. 35 
2. Design: Retrospective, case series. 36 
3. Subjects, Participants, and/or Controls: Children diagnosed with 37 
choroideraemia at a single institution.  38 
4. Methods, Intervention, or Testing: Subjects were identified using an electronic 39 
patient record system. Case notes and retinal imaging (colour fundus photography 40 
(CFP), spectral domain optical coherence tomography (SD-OCT) and fundus 41 
autofluorescence (FAF)) were then reviewed. The results of genetic testing were 42 
also recorded. 43 
5. Main Outcome Measures: Presenting symptoms, visual acuity, fundus changes 44 
(CFP, SD-OCT, FAF) and CHM sequencing results. 45 
6. Results: 29 patients were identified with a mean age at referral of 9 years (range 46 
3-16).  CHM mutations were identified in 15/19 patients tested. Nyctalopia was 47 
the predominant symptom (66%). 5/29 patients were asymptomatic at 48 
presentation. At the final follow up visit (mean age 16, range 7-26) the majority 49 
maintained excellent visual acuity (mean 0.98 +/- 0.13 decimalized Snellen 50 
acuity). The first sign of retinopathy was widespread pigment clumping at the 51 
level of the retinal pigment epithelium (RPE). This later evolved to chorioretinal 52 
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atrophy, most marked in the mid-peripheral retina. Peripapillary atrophy was also 53 
an early feature, and progressive in nature. Three different zones of FAF change 54 
were visible. Persistence of the inner retinal layers, detected by SD-OCT, was 55 
visible at presentation in 15/27 patients. Subfoveal choroidal thickness decreased 56 
with age whilst central retinal thickness increased over a similar interval. Four 57 
patients in whom visual acuity decreased over the follow-up period recorded a 58 
reduction in central retinal thickness. 59 
7. Conclusions:  Progressive structural changes occur at a time when central visual 60 
function is maintained. Pigmentary changes at the level of the RPE occur early in 61 
the disease course. Peripapillary chorioretinal atrophy, central retinal thickness 62 
and subfoveal choroidal thickness are likely to be valuable in monitoring disease 63 
progression, and should be considered as potential biomarkers in future 64 
therapeutic trials.  65 
66 
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Clinical and Genetic Features of Choroideraemia in Childhood 67 
 68 
Introduction 69 
 70 
Choroideraemia (CHM, OMIM 303100) is a rare, X-linked progressive retinal 71 
dystrophy that is estimated to affect between 1 in 50,000 to 1 in 100,000 72 
individuals. Typically male patients experience childhood-onset nyctalopia, 73 
followed by loss of peripheral visual field in their teenage years. However, most 74 
retain good central acuity into the fifth decade of life. Carrier females typically 75 
display a phenotype consistent with random X chromosome inactivation, 76 
manifesting as irregular pigmentary change in the fundus. Usually their 77 
symptoms if any are much milder than affected males, however a minority may 78 
be significantly affected, but usually with less severe disease than for male 79 
relatives.1   80 
 81 
Choroideraemia occurs due to dysfunction of the Rab escort protein-1 (REP-1), a 82 
consequence of pathological genetic variation in the CHM gene.2 Single point 83 
mutations (coding, splice site, intronic) or small structural variants cause 84 
isolated retinal disease, but occasionally contiguous gene deletion syndromes 85 
occur where the CHM phenotype may be seen in conjunction with extraocular 86 
disease.1 Irrespective of the genotype, the overall effect is of loss of REP-1 87 
function. REP-1 is one of two Rab escort proteins (REPs), cytosolic molecular 88 
chaperones that facilitate Rab prenylation - the addition of geranylgeranyl 89 
groups, which enable reversible anchoring of Rab proteins to the cell 90 
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membrane.3  91 
The mechanism of retinal degeneration however is poorly understood, and there 92 
is still uncertainty regarding which cell type(s) are primarily affected.4 To 93 
improve our understanding in this key area, and in view of on-going and 94 
anticipated interventional trials of novel therapies, the present study reviews the 95 
anatomical characteristics of CHM in the paediatric population, with the aim of 96 
describing the earliest cellular patterns of degeneration. 97 
Methods 98 
A retrospective review of the electronic patient record system (OpenEyes, 99 
Moorfields Eye Hospital (MEH), London, UK) was used to identify all children 100 
(under the age of 17) diagnosed with choroideraemia. The patients’ notes were 101 
then reviewed along with the results of retinal imaging and molecular genetic 102 
investigations.  103 
Retinal imaging was performed using the Spectralis confocal scanning laser 104 
ophthalmoscope (cSLO) (Heidelberg Engineering, Heidelberg, Germany) to 105 
obtain spectral domain optical coherence tomography (SD-OCT) and 488nm 106 
fundus autofluorescence (FAF) images. Subfoveal retinal and choroidal thickness 107 
was assessed using the caliper function of the Heidelberg Eye Explorer software 108 
(Heidelberg Engineering). The former was measured between the internal 109 
limiting membrane (ILM) to the inner aspect of the retinal pigment 110 
epithelium/Bruch membrane (RPE/BM) complex, whilst the latter was 111 
measured from the outer aspect of the RPE/BM complex to anterior scleral 112 
boundary. Retinal loci retaining physiological levels of autofluorescence were 113 
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measured using the “draw a region” function of the same software.  114 
Genetic testing was performed by Sanger sequencing the entire coding sequence 115 
of CHM at the national genetics reference laboratory (NGRL), Manchester, UK.  If 116 
no variants were identified, multiplex ligation dependent probe amplification 117 
(MLPA) analysis was then performed in the same laboratory.  118 
Statistical differences in paired data were analysed using a two-tailed paired 119 
Student’s T-test. For unpaired data a two sample, equal variance, two-tailed T-120 
test was performed.  121 
This study was approved by the local research ethics committee, and all 122 
investigations were conducted in accordance with the principles of the 123 
Declaration of Helsinki. 124 
Results 125 
Clinical Characteristics 126 
29 patients (28 pedigrees) were identified with a clinical diagnosis of CHM 127 
where the initial visit was under the age of 17 years. Two patients were seen 128 
only once, as they were referred for a second opinion regarding diagnosis. For all 129 
other patients longitudinal data were available. The mean age at referral was 9 130 
years (range 3-16) and at final follow up was 16 years (range 7-26). Patient 131 
demographics are presented in Table 1.  132 
Genetic testing was initiated in 19/29 cases and pathogenic variants were 133 
identified in all but four cases (three pedigrees) (Table 1). Two of these three 134 
families described a family history of eye disease, where affected male relatives 135 
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were more severely affected than females. In all three cases mothers displayed 136 
the typical fundus features of a CHM carrier, despite the molecular cause 137 
remaining elusive. In contrast, for one proband with molecularly confirmed 138 
disease (patient 23) clinical examination of his mother was unremarkable, and 139 
genetic testing confirmed the absence of her son’s mutation. It is possible that 140 
maternal germline mosaicism could account for this family’s disease, although 141 
this hypothesis was not tested further. In 10/29 cases (nine families) no testing 142 
was performed; in all cases there was either an affected male relative (n=5) or 143 
characteristic retinal changes present in the mother (n=5), consequently the 144 
diagnosis was never in doubt.   145 
The majority of patients were symptomatic at disease discovery, with 66% 146 
(19/29) reporting difficulty seeing in the dark as their major concern, whilst in a 147 
minority (17% or 5/29), the primary complaint was of peripheral field loss. A 148 
similar number were asymptomatic (5/29), although this group did not differ 149 
significantly in age from those who were symptomatic (mean age symptomatic = 150 
9.6 years versus asymptomatic = 6.8 years, p = 0.15). In two cases the disease 151 
was discovered on routine examination for assessment of refractive error. For 152 
the majority of cases, central visual acuity at the initial visit was excellent (0.92 153 
+/- 0.19 decimalized Snellen acuity). Correction of any refractive error resulted 154 
in further improvement during the follow up period such that normal acuity was 155 
maintained at the final clinic visit (mean acuity 0.98 +/- 0.13 decimalized Snellen 156 
acuity).  157 
Retinal Imaging 158 
Colour fundus photography from at least one clinic visit was available for review 159 
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in 25/29 cases. The earliest identifiable changes were seen throughout the 160 
peripheral retina, as pigmentary disturbance, thought to be external to the retina 161 
and at the level of the RPE. The changes appeared as granular clumps of 162 
pigmentation, finer at the macula than in the periphery (Figure 1a, b). Also 163 
present at an early stage was peripapillary retinal atrophy (Figure 1c). With time 164 
the areas of peripheral retina covered with pigmentary change evolved into 165 
areas of atrophy, particularly well defined in the mid-peripheral retina, between 166 
the vascular arcades and the equator (Fig 1c). Interspersed between these areas 167 
of atrophy were regions that retained pigmentation, although ultimately these 168 
were lost as the disease progressed. Later, regions of pigmented plaques were 169 
visible. The peri and para-papillary atrophy was progressive, and advanced in a 170 
centrifugal manner towards the macula (Figure 1d-g).  171 
All four asymptomatic cases displayed significant retinal signs of disease. In 172 
cases where the far periphery was imaged, the anterior retina appeared to have 173 
more diffuse changes, with well circumscribed areas of atrophy being found 174 
posterior to this (patients 10,15, 20, 21, 24, 26) (Figure h, i). In the most 175 
advanced stages of disease, only the largest choroidal vessels were visible, with 176 
complete loss of the choriocapillaris. The retinal vasculature however remained 177 
subjectively unchanged, even when only a small central island of functioning 178 
retina remained.  179 
Fundus autofluorescence imaging was undertaken in 25/29 cases, with follow up 180 
data available for 4/25. In all patients the area of normal FAF appeared to 181 
correlate with age, although there was significant variation between individuals. 182 
Eyes of the same patient however demonstrated significant symmetry (Student’s 183 
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T-test, p=0.57). Where follow up data was available, all eyes demonstrated a 184 
reduction in retained macular autofluorescence, with the most severely affected 185 
eyes recording a slower rate of progression compared with those with milder 186 
disease (patients 1 and 6 versus patients 5 and 7, Table 1). Loss of peri-papillary 187 
autofluorescence was recorded early in the disease course, and this advanced as 188 
the disease progressed (Figure 2a, b). In most cases, three patterns of FAF were 189 
observed at the posterior pole: normal, speckled and absent (Figure 2c, d). 190 
SD-OCT was used for both quantitative and qualitative analysis of retinal and 191 
choroidal structure. Images were available for review in 27/29 cases, with 192 
longitudinal data available for retinal and choroidal thickness in 17/27. 193 
Significant fovea-involving macular oedema was not observed, consistent with 194 
the excellent visual acuities recorded (Figure 3a, b). Localised intra-retinal 195 
oedema was however seen at more peripheral loci, between zones of atrophic 196 
and healthy tissue (“transition zones”) where active degeneration would be 197 
expected (Figure 3c). Outer retinal tubulation (ORT) was identified in similar 198 
regions, in zones of recent atrophy adjacent to visibly normal tissue (Figure 3d). 199 
Importantly ORT was never observed in regions of well-established atrophy, 200 
suggesting residual photoreceptors and RPE are required (Figure 3d).  201 
In 15/27 cases persistence of inner retinal layers (foveal hypoplasia) was visible 202 
on macular line scans through the fovea (Figure 3a, b). Intraretinal oedema was 203 
not evident in any of these cases. In 12/27 patients a normal foveal contour was 204 
observed. On one scan (patient 10) posterior bowing of the line presumed to 205 
represent Bruch membrane was observed in association with an irregular dome 206 
shaped hyper-reflective mass (Figure 3e). This co-localised with a region of 207 
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subretinal fibrosis and was thought to relate to prior choroidal 208 
neovascularisation (CNVM). Mild cystic spaces were identified in the inner 209 
nuclear layer (INL) over regions where there was outer retinal architecture 210 
distortion.  211 
Subfoveal retinal and choroidal thickness measurements were recorded from 212 
OCT scans. Central choroidal thickness decreased with increasing age, with a 213 
mean thickness of 292 ± 71μm early in the disease course (mean age 12), that 214 
later reduced to 257 ± 76μm (mean age 15, n=36 eyes) (p<0.00001). Over the 215 
same time interval the subfoveal retinal thickness increased significantly, from 216 
232 ± 46μm to 246 ± 35μm (p=0.04) without visible retinal cysts. Whilst the 217 
decrease in choroidal thickness was observed in all cases, a minority of eyes 218 
showed a reduction in retinal thickness (n=8) rather than an increase (n=28). 219 
Eyes in which a minor loss of acuity was noted (patients 23, 24, 27, 28) recorded 220 
a mean reduction in retinal thickness (mean 7.6 ± 13.2μm) contrasting with eyes 221 
where vision was maintained, which recorded a mean increase in retinal 222 
thickness (11.6 ± 16.1μm; p=0.017). 223 
 224 
Discussion 225 
 226 
This work provides a detailed retrospective analysis of the structural changes 227 
seen in a large cohort of children with CHM. Until now, findings in this age group 228 
have been scarce, and the few reported cases have been lost within a larger 229 
volume of adult data. Consequently the earliest features of disease have been 230 
poorly described. 231 
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 232 
Unlike most paediatric retinal dystrophies, which are discovered as a result of 233 
reduced central acuity, CHM is most commonly identified as a result of 234 
nyctalopia, and to a lesser degree loss of peripheral visual field. The youngest 235 
patient to experience symptoms in this series was five years old, and so it is 236 
likely that signs of retinopathy are present, yet undiscovered, at an early age. 237 
With one exception, Patient 19, high refractive error was not a significant feature 238 
of disease in keeping with other reports.5 The low refractive error associated 239 
with CHM also contrasts with the high myopia of X-linked retinitis pigmentosa 240 
(XLRP), a potential phenocopy early in the disease course.  241 
 242 
Maintenance of normal visual acuity is also in keeping with the absence of 243 
significant macular oedema (MO), a feature reported to occur in up to 62.5% of 244 
adult patients.6 Early on in the disease course, a small increase in central retinal 245 
thickness was noted in all patients with good central vision, perhaps indicating 246 
subclinical microcystic oedema which was not easily visualised on OCT B scans. 247 
Whilst the vast majority of eyes maintain baseline acuity, seven eyes recorded a 248 
small deterioration in vision over the follow up period. The subfoveal retinal 249 
thickness decreased in these eyes, acting perhaps as a surrogate marker of early 250 
photoreceptor death. Over the same time period, almost all eyes showed a 251 
reduction in subfoveal choroidal thickness. Despite the recognition of choroidal 252 
atrophy in the first description of CHM, objective changes in choroidal thickness 253 
have not previously been reported. Here we record a measurable reduction in 254 
subfoveal choroidal thickness, detected at a time when central retinal function is 255 
otherwise unaffected, and outside the zone of visible degeneration. This 256 
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discovery offers great clinical utility, as SD-OCT measurements of both retinal 257 
and choroidal thickness, which have a low test-retest variability and can be 258 
reliably obtained in virtually all subjects, will be useful both for monitoring 259 
disease progression as well as response to novel therapies, independently of 260 
visual acuity data. 261 
 262 
Colour fundus photography was useful in identifying different stages of retinal 263 
degeneration. Fourier et al. have previously used the same method to classify the 264 
fundus changes present in female carriers of CHM mutations – mild RPE changes, 265 
patchy RPE degeneration or confluent chorioretinal atrophy.7 Identical 266 
observations are reported here, but now in a paediatric cohort. Widespread 267 
pigment clumping at the level of the RPE was identified as the earliest sign of 268 
disease. This pigmentary response is very different to that observed in typical 269 
retinitis pigmentosa, where RPE cells migrate into the neurosensory retina as a 270 
consequence of photoreceptor cell death, usually resulting in a branched 271 
network of “spicules”. The pigment responsible for the observed changes has 272 
two potential sources - melanosomes within the RPE, and melanocytes, thought 273 
to be resident within the stroma of the choroid, both of which show significant 274 
degeneration but for unknown reasons.1 What is known is that REP-1 275 
dysfunction, consequent upon CHM mutation, results in reduced Rab 276 
prenylation.8 Each Rab is uniquely sensitive to this process, based on its intrinsic 277 
affinity for REP-1. Rab27a has a particularly low affinity when compared to other 278 
Rabs, and as a result in a competitive environment, undergoes little prenylation.8 279 
Rab27a dysfunction causes Griscelli syndrome (OMIM 607624), a disorder 280 
characterized by hypomelanosis and immunological abnormalities. Rab27a is 281 
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now recognized not only as an important regulator of melanin transport in 282 
melanosome, but also in polarized trafficking in (non-secretory) epithelial cells.8 283 
It is therefore plausible that the observed retinal pigment clumping represents a 284 
visible manifestation of local Rab27a-associated melanosome transport 285 
dysfunction, and that other vesicle trafficking problems co-exist. Ultimately these 286 
result in RPE disease and death. Unlike choroidal melanocytes, the RPE 287 
melanosomes are fully mature at birth, and are incapable of renewal, perhaps 288 
explaining why the RPE is so sensitive to REP-1 dysfunction.9  289 
 290 
Following widespread pigmentary changes, well-defined regions of atrophy 291 
develop, most commonly in the post-equatorial region, just outside the vascular 292 
arcades. These changes advance centripetally whilst the far periphery seems to 293 
be relatively spared. It is possible that this stereotypical feature of disease may 294 
either relate to the underlying arrangement of lobular choroidal anatomy, 295 
regional differences in RPE metabolism or indeed both, and explain why these 296 
changes are not so readily seen in the anterior retina. A similar pattern of retinal 297 
degeneration occurs in gyrate atrophy (OMIM 258870) and dominant mutation 298 
of RPE65, but may also be observed in late-onset retinal degeneration (L-ORD, 299 
OMIM 605670), all conditions that are thought to affect the RPE.10  300 
 301 
Peri-papillary disease has been poorly described to date. In this series all 302 
patients, even the youngest showed significant para- and peri-papillary atrophy. 303 
Whilst objective analysis of the retinal nerve fibre layer in this region has been 304 
performed, detailed assessment of the surrounding outer retina changes has not 305 
been reported.11-13 It is unclear why patients with CHM have early peri-papillary 306 
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involvement, whilst in retinal disease associated with biallelic ABCA4 mutations 307 
this retinal region is spared. One possibility is that choroidal blood flow may 308 
influence the rate of progression, as degeneration in CHM appears to 309 
preferentially occur in loci where the choroid is at its thinnest.  310 
 311 
In addition to causing a progressive retinopathy, mutation of CHM could 312 
theoretically also result in anatomical changes present at birth or shortly 313 
thereafter. In keeping with this hypothesis, persistence of the inner retinal layers 314 
was identified in approximately half of the cases (15/27), a similar finding to 315 
that seen in patients with another disorder of hypomelanosis – albinism, where 316 
variable degrees of foveal hypoplasia are observed.14 In some cases however, 317 
very dense scans through fixation were not obtained, so it remains possible that 318 
a normal foveola exists but was just not captured. Usually however, the foveal pit 319 
is large enough to be identifiable on at least two normal density macula line 320 
scans, as such we feel that its absence is not due to technical factors. Again, in 321 
keeping with incomplete foveal maturation, changes in central foveal 322 
autofluorescence were also noted, perhaps indicating subtle alterations in the 323 
amount of luteal pigment within Henle layer, a finding otherwise unexpected in 324 
the earliest stages of many other retinal dystrophies. Lastly, macular hole 325 
formation is an extremely uncommon complication of inherited retinal disease, 326 
with only scattered single cases identified.15 Unusually, a recent report describes 327 
the prevalence of macular hole formation in patients with CHM at 10%, again 328 
hinting at a possible underlying developmental macular anomaly.16 Alternatively 329 
this may either relate to a high prevalence of pre-retinal glial cell proliferation in 330 
advanced disease resulting in mechanical traction from epiretinal membrane 331 
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tissue or the consequence of chronic cystic change. 332 
 333 
Another feature associated with chorioretinal atrophy is ORT.17 In our study ORT 334 
was notably absent from regions of established atrophy, and only found adjacent 335 
to healthy tissue, suggesting that the remaining (overhanging) photoreceptors 336 
may organise themselves around residual islands of RPE cells. Other signs of 337 
advanced atrophy, such as “ghost drusen” (highly reflective pyramidal 338 
structures), a common feature of advanced L-ORD (unpublished observation), 339 
are absent. Similarly, although late-stage retinal disease may also be complicated 340 
by choroidal neovascularization (CNVM), this is thought to be an uncommon 341 
feature of end-stage CHM. Cases of presumed CNVM, similar to that observed in 342 
patient 10 do exist, and have been reported by others.18 The true prevalence of 343 
CNVM will be hard to determine however, as generally only symptomatic 344 
patients are identified. 345 
 346 
 347 
This study provides a detailed description of the clinical, imaging and genetic 348 
findings present in a large cohort of paediatric patients with CHM. We propose 349 
that the observed widespread pigmentary changes are a visible consequence of 350 
Rab27a dysfunction, and highlight novel anatomical changes present both in the 351 
peri-papillary retina and inner retina at the fovea. In addition, we have presented 352 
SD-OCT data demonstrating a reduction in subfoveal choroidal thickness with 353 
disease progression, and a simultaneous increase in foveal retinal thickness, both 354 
of which occur whilst visual acuity is maintained. Deterioration in visual acuity is 355 
uncommon in CHM in childhood but when it does occur it is associated with a 356 
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reduction in retinal thickness. The anatomical changes described herein were 357 
evident even in the youngest patients, and hence must occur early in the disease 358 
course. We envisage that these objective imaging parameters will become useful 359 
tools for monitoring change, both in prospective natural history studies of CHM 360 
and in response to future treatments. 361 
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LEGENDS 414 
Figure 1: Colour fundus photography in patients with choroideraemia. (a) Early, 415 
fine, granular pigmentary changes in the central macula and around the vascular 416 
arcades, (b) larger pigment plaques in the temporal periphery. (c) Four years 417 
later the regions of pigmentary change have now evolved to atrophy, also 418 
involving the peripapillary retina (patient 4). Images (d, e) and (f, g) taken from 419 
patient 5 two years apart, highlighting progressive PPA. (h, i) Optos 420 
pseudocolour images from patient 7 highlighting well defined scalloped atrophy 421 
and pigment plaques with less well-defined anterior changes.  422 
 423 
Figure 2: Fundus autofluorescence images demonstrating the progression in 424 
peripapillary atrophy in patient 2 (a, b). Three distinct zones of autofluorescence 425 
are visible in patient 6 – complete absence, speckled and normal (c, d).  426 
 427 
Figure 3: Spectral domain optical coherence tomography in patients with 428 
choroideraemia. Approximately half of all eyes demonstrated persistence of the 429 
inner retinal layers (a, b). In regions immediately adjacent to atrophic retina, loss 430 
of retinal structure was associated with the presence of cystic spaces in either 431 
the outer or inner nuclear layers (c). Outer retinal tubulations were observed 432 
only in regions retaining small islands of retinal pigment epithelium, but never in 433 
areas of frank atrophy (d). Imaging the left eye of Patient 10 shows the presence 434 
of highly reflective subretinal material, suggestive of prior choroidal 435 
neovascularization (e). 436 
 437 
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Clinical and Genetic Features of Choroideraemia in Childhood. 31 
1. Objective or Purpose: To review the functional and anatomical characteristics of 32 
choroideraemia in the paediatric population, aiming to describing the earliest 33 
features of disease, and identify biomarkers useful for monitoring disease 34 
progression. 35 
2. Design: Retrospective, case series. 36 
3. Subjects, Participants, and/or Controls: Children diagnosed with 37 
choroideraemia at a single institution.  38 
4. Methods, Intervention, or Testing: Subjects were identified using an electronic 39 
patient record system. Case notes and retinal imaging (colour fundus photography 40 
(CFP), spectral domain optical coherence tomography (SD-OCT) and fundus 41 
autofluorescence (FAF)) were then reviewed. The results of genetic testing were 42 
also recorded. 43 
5. Main Outcome Measures: Presenting symptoms, visual acuity, fundus changes 44 
(CFP, SD-OCT, FAF) and CHM sequencing results. 45 
6. Results: 29 patients were identified with a mean age at referral of 9 years (range 46 
3-16).  CHM mutations were identified in 15/19 patients tested. Nyctalopia was 47 
the predominant symptom (66%). 5/29 patients were asymptomatic at 48 
presentation. At the final follow up visit (mean age 16, range 7-26) the majority 49 
maintained excellent visual acuity (mean 0.98 +/- 0.13 decimalized Snellen 50 
acuity). The first sign of retinopathy was widespread pigment clumping at the 51 
level of the retinal pigment epithelium (RPE). This later evolved to chorioretinal 52 
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atrophy, most marked in the mid-peripheral retina. Peripapillary atrophy was also 53 
an early feature, and progressive in nature. Three different zones of FAF change 54 
were visible. Persistence of the inner retinal layers, detected by SD-OCT, was 55 
visible at presentation in 15/27 patients. Subfoveal choroidal thickness decreased 56 
with age whilst central retinal thickness increased over a similar interval. Four 57 
patients in whom visual acuity decreased over the follow-up period recorded a 58 
reduction in central retinal thickness. 59 
7. Conclusions:  Progressive structural changes occur at a time when central visual 60 
function is maintained. Pigmentary changes at the level of the RPE occur early in 61 
the disease course. Peripapillary chorioretinal atrophy, central retinal thickness 62 
and subfoveal choroidal thickness are likely to be valuable in monitoring disease 63 
progression, and should be considered as potential biomarkers in future 64 
therapeutic trials.  65 
66 
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Clinical and Genetic Features of Choroideraemia in Childhood 67 
 68 
Introduction 69 
 70 
Choroideraemia (CHM, OMIM 303100) is a rare, X-linked progressive retinal 71 
dystrophy that is estimated to affect between 1 in 50,000 to 1 in 100,000 72 
individuals. Typically male patients experience childhood-onset nyctalopia, 73 
followed by loss of peripheral visual field in their teenage years. However, most 74 
retain good central acuity into the fifth decade of life. Carrier females typically 75 
display a phenotype consistent with random X chromosome inactivation, 76 
manifesting as irregular pigmentary change in the fundus. Usually their 77 
symptoms if any are much milder than affected males, however a minority may 78 
be significantly affected, but usually with less severe disease than for male 79 
relatives.1   80 
 81 
Choroideraemia occurs due to dysfunction of the Rab escort protein-1 (REP-1), a 82 
consequence of pathological genetic variation in the CHM gene.2 Single point 83 
mutations (coding, splice site, intronic) or small structural variants cause 84 
isolated retinal disease, but occasionally contiguous gene deletion syndromes 85 
occur where the CHM phenotype may be seen in conjunction with extraocular 86 
disease.1 Irrespective of the genotype, the overall effect is of loss of REP-1 87 
function. REP-1 is one of two Rab escort proteins (REPs), cytosolic molecular 88 
chaperones that facilitate Rab prenylation - the addition of geranylgeranyl 89 
groups, which enable reversible anchoring of Rab proteins to the cell 90 
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membrane.3  91 
The mechanism of retinal degeneration however is poorly understood, and there 92 
is still uncertainty regarding which cell type(s) are primarily affected.4 To 93 
improve our understanding in this key area, and in view of on-going and 94 
anticipated interventional trials of novel therapies, the present study reviews the 95 
anatomical characteristics of CHM in the paediatric population, with the aim of 96 
describing the earliest cellular patterns of degeneration. 97 
Methods 98 
A retrospective review of the electronic patient record system (OpenEyes, 99 
Moorfields Eye Hospital (MEH), London, UK) was used to identify all children 100 
(under the age of 17) diagnosed with choroideraemia. The patients’ notes were 101 
then reviewed along with the results of retinal imaging and molecular genetic 102 
investigations.  103 
Retinal imaging was performed using the Spectralis confocal scanning laser 104 
ophthalmoscope (cSLO) (Heidelberg Engineering, Heidelberg, Germany) to 105 
obtain spectral domain optical coherence tomography (SD-OCT) and 488nm 106 
fundus autofluorescence (FAF) images. Subfoveal retinal and choroidal thickness 107 
was assessed using the caliper function of the Heidelberg Eye Explorer software 108 
(Heidelberg Engineering). The former was measured between the internal 109 
limiting membrane (ILM) to the inner aspect of the retinal pigment 110 
epithelium/Bruch membrane (RPE/BM) complex, whilst the latter was 111 
measured from the outer aspect of the RPE/BM complex to anterior scleral 112 
boundary. Retinal loci retaining physiological levels of autofluorescence were 113 
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measured using the “draw a region” function of the same software.  114 
Genetic testing was performed by Sanger sequencing the entire coding sequence 115 
of CHM at the national genetics reference laboratory (NGRL), Manchester, UK.  If 116 
no variants were identified, multiplex ligation dependent probe amplification 117 
(MLPA) analysis was then performed in the same laboratory.  118 
Statistical differences in paired data were analysed using a two-tailed paired 119 
Student’s T-test. For unpaired data a two sample, equal variance, two-tailed T-120 
test was performed.  121 
This study was approved by the local research ethics committee, and all 122 
investigations were conducted in accordance with the principles of the 123 
Declaration of Helsinki. 124 
Results 125 
Clinical Characteristics 126 
29 patients (28 pedigrees) were identified with a clinical diagnosis of CHM 127 
where the initial visit was under the age of 17 years. Two patients were seen 128 
only once, as they were referred for a second opinion regarding diagnosis. For all 129 
other patients longitudinal data were available. The mean age at referral was 9 130 
years (range 3-16) and at final follow up was 16 years (range 7-26). Patient 131 
demographics are presented in Table 1.  132 
Genetic testing was initiated in 19/29 cases and pathogenic variants were 133 
identified in all but four cases (three pedigrees) (Table 1). Two of these three 134 
families described a family history of eye disease, where affected male relatives 135 
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were more severely affected than females. In all three cases mothers displayed 136 
the typical fundus features of a CHM carrier, despite the molecular cause 137 
remaining elusive. In contrast, for one proband with molecularly confirmed 138 
disease (patient 23) clinical examination of his mother was unremarkable, and 139 
genetic testing confirmed the absence of her son’s mutation. It is possible that 140 
maternal germline mosaicism could account for this family’s disease, although 141 
this hypothesis was not tested further. In 10/29 cases (nine families) no testing 142 
was performed; in all cases there was either an affected male relative (n=5) or 143 
characteristic retinal changes present in the mother (n=5), consequently the 144 
diagnosis was never in doubt.   145 
The majority of patients were symptomatic at disease discovery, with 66% 146 
(19/29) reporting difficulty seeing in the dark as their major concern, whilst in a 147 
minority (17% or 5/29), the primary complaint was of peripheral field loss. A 148 
similar number were asymptomatic (5/29), although this group did not differ 149 
significantly in age from those who were symptomatic (mean age symptomatic = 150 
9.6 years versus asymptomatic = 6.8 years, p = 0.15). In two cases the disease 151 
was discovered on routine examination for assessment of refractive error. For 152 
the majority of cases, central visual acuity at the initial visit was excellent (0.92 153 
+/- 0.19 decimalized Snellen acuity). Correction of any refractive error resulted 154 
in further improvement during the follow up period such that normal acuity was 155 
maintained at the final clinic visit (mean acuity 0.98 +/- 0.13 decimalized Snellen 156 
acuity).  157 
Retinal Imaging 158 
Colour fundus photography from at least one clinic visit was available for review 159 
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in 25/29 cases. The earliest identifiable changes were seen throughout the 160 
peripheral retina, as pigmentary disturbance, thought to be external to the retina 161 
and at the level of the RPE. The changes appeared as granular clumps of 162 
pigmentation, finer at the macula than in the periphery (Figure 1a, b). Also 163 
present at an early stage was peripapillary retinal atrophy (Figure 1c). With time 164 
the areas of peripheral retina covered with pigmentary change evolved into 165 
areas of atrophy, particularly well defined in the mid-peripheral retina, between 166 
the vascular arcades and the equator (Fig 1c). Interspersed between these areas 167 
of atrophy were regions that retained pigmentation, although ultimately these 168 
were lost as the disease progressed. Later, regions of pigmented plaques were 169 
visible. The peri and para-papillary atrophy was progressive, and advanced in a 170 
centrifugal manner towards the macula (Figure 1d-g).  171 
All four asymptomatic cases displayed significant retinal signs of disease. In 172 
cases where the far periphery was imaged, the anterior retina appeared to have 173 
more diffuse changes, with well circumscribed areas of atrophy being found 174 
posterior to this (patients 10,15, 20, 21, 24, 26) (Figure h, i). In the most 175 
advanced stages of disease, only the largest choroidal vessels were visible, with 176 
complete loss of the choriocapillaris. The retinal vasculature however remained 177 
subjectively unchanged, even when only a small central island of functioning 178 
retina remained.  179 
Fundus autofluorescence imaging was undertaken in 25/29 cases, with follow up 180 
data available for 4/25. In all patients the area of normal FAF appeared to 181 
correlate with age, although there was significant variation between individuals. 182 
Eyes of the same patient however demonstrated significant symmetry (Student’s 183 
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T-test, p=0.57). Where follow up data was available, all eyes demonstrated a 184 
reduction in retained macular autofluorescence, with the most severely affected 185 
eyes recording a slower rate of progression compared with those with milder 186 
disease (patients 1 and 6 versus patients 5 and 7, Table 1). Loss of peri-papillary 187 
autofluorescence was recorded early in the disease course, and this advanced as 188 
the disease progressed (Figure 2a, b). In most cases, three patterns of FAF were 189 
observed at the posterior pole: normal, speckled and absent (Figure 2c, d). 190 
SD-OCT was used for both quantitative and qualitative analysis of retinal and 191 
choroidal structure. Images were available for review in 27/29 cases, with 192 
longitudinal data available for retinal and choroidal thickness in 17/27. 193 
Significant fovea-involving macular oedema was not observed, consistent with 194 
the excellent visual acuities recorded (Figure 3a, b). Localised intra-retinal 195 
oedema was however seen at more peripheral loci, between zones of atrophic 196 
and healthy tissue (“transition zones”) where active degeneration would be 197 
expected (Figure 3c). Outer retinal tubulation (ORT) was identified in similar 198 
regions, in zones of recent atrophy adjacent to visibly normal tissue (Figure 3d). 199 
Importantly ORT was never observed in regions of well-established atrophy, 200 
suggesting residual photoreceptors and RPE are required (Figure 3d).  201 
In 15/27 cases persistence of inner retinal layers (foveal hypoplasia) was visible 202 
on macular line scans through the fovea (Figure 3a, b). Intraretinal oedema was 203 
not evident in any of these cases. In 12/27 patients a normal foveal contour was 204 
observed. On one scan (patient 10) posterior bowing of the line presumed to 205 
represent Bruch membrane was observed in association with an irregular dome 206 
shaped hyper-reflective mass (Figure 3e). This co-localised with a region of 207 
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subretinal fibrosis and was thought to relate to prior choroidal 208 
neovascularisation (CNVM). Mild cystic spaces were identified in the inner 209 
nuclear layer (INL) over regions where there was outer retinal architecture 210 
distortion.  211 
Subfoveal retinal and choroidal thickness measurements were recorded from 212 
OCT scans. Central choroidal thickness decreased with increasing age, with a 213 
mean thickness of 292 ± 71μm early in the disease course (mean age 12), that 214 
later reduced to 257 ± 76μm (mean age 15, n=36 eyes) (p<0.00001). Over the 215 
same time interval the subfoveal retinal thickness increased significantly, from 216 
232 ± 46μm to 246 ± 35μm (p=0.04) without visible retinal cysts. Whilst the 217 
decrease in choroidal thickness was observed in all cases, a minority of eyes 218 
showed a reduction in retinal thickness (n=8) rather than an increase (n=28). 219 
Eyes in which a minor loss of acuity was noted (patients 23, 24, 27, 28) recorded 220 
a mean reduction in retinal thickness (mean 7.6 ± 13.2μm) contrasting with eyes 221 
where vision was maintained, which recorded a mean increase in retinal 222 
thickness (11.6 ± 16.1μm; p=0.017). 223 
 224 
Discussion 225 
 226 
This work provides a detailed retrospective analysis of the structural changes 227 
seen in a large cohort of children with CHM. Until now, findings in this age group 228 
have been scarce, and the few reported cases have been lost within a larger 229 
volume of adult data. Consequently the earliest features of disease have been 230 
poorly described. 231 
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 232 
Unlike most paediatric retinal dystrophies, which are discovered as a result of 233 
reduced central acuity, CHM is most commonly identified as a result of 234 
nyctalopia, and to a lesser degree loss of peripheral visual field. The youngest 235 
patient to experience symptoms in this series was five years old, and so it is 236 
likely that signs of retinopathy are present, yet undiscovered, at an early age. 237 
With one exception, Patient 19, high refractive error was not a significant feature 238 
of disease in keeping with other reports.5 The low refractive error associated 239 
with CHM also contrasts with the high myopia of X-linked retinitis pigmentosa 240 
(XLRP), a potential phenocopy early in the disease course.  241 
 242 
Maintenance of normal visual acuity is also in keeping with the absence of 243 
significant macular oedema (MO), a feature reported to occur in up to 62.5% of 244 
adult patients.6 Early on in the disease course, a small increase in central retinal 245 
thickness was noted in all patients with good central vision, perhaps indicating 246 
subclinical microcystic oedema which was not easily visualised on OCT B scans. 247 
Whilst the vast majority of eyes maintain baseline acuity, seven eyes recorded a 248 
small deterioration in vision over the follow up period. The subfoveal retinal 249 
thickness decreased in these eyes, acting perhaps as a surrogate marker of early 250 
photoreceptor death. Over the same time period, almost all eyes showed a 251 
reduction in subfoveal choroidal thickness. Despite the recognition of choroidal 252 
atrophy in the first description of CHM, objective changes in choroidal thickness 253 
have not previously been reported. Here we record a measurable reduction in 254 
subfoveal choroidal thickness, detected at a time when central retinal function is 255 
otherwise unaffected, and outside the zone of visible degeneration. This 256 
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discovery offers great clinical utility, as SD-OCT measurements of both retinal 257 
and choroidal thickness, which have a low test-retest variability and can be 258 
reliably obtained in virtually all subjects, will be useful both for monitoring 259 
disease progression as well as response to novel therapies, independently of 260 
visual acuity data. 261 
 262 
Colour fundus photography was useful in identifying different stages of retinal 263 
degeneration. Fourier et al. have previously used the same method to classify the 264 
fundus changes present in female carriers of CHM mutations – mild RPE changes, 265 
patchy RPE degeneration or confluent chorioretinal atrophy.7 Identical 266 
observations are reported here, but now in a paediatric cohort. Widespread 267 
pigment clumping at the level of the RPE was identified as the earliest sign of 268 
disease. This pigmentary response is very different to that observed in typical 269 
retinitis pigmentosa, where RPE cells migrate into the neurosensory retina as a 270 
consequence of photoreceptor cell death, usually resulting in a branched 271 
network of “spicules”. The pigment responsible for the observed changes has 272 
two potential sources - melanosomes within the RPE, and melanocytes, thought 273 
to be resident within the stroma of the choroid, both of which show significant 274 
degeneration but for unknown reasons.1 What is known is that REP-1 275 
dysfunction, consequent upon CHM mutation, results in reduced Rab 276 
prenylation.8 Each Rab is uniquely sensitive to this process, based on its intrinsic 277 
affinity for REP-1. Rab27a has a particularly low affinity when compared to other 278 
Rabs, and as a result in a competitive environment, undergoes little prenylation.8 279 
Rab27a dysfunction causes Griscelli syndrome (OMIM 607624), a disorder 280 
characterized by hypomelanosis and immunological abnormalities. Rab27a is 281 
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now recognized not only as an important regulator of melanin transport in 282 
melanosome, but also in polarized trafficking in (non-secretory) epithelial cells.8 283 
It is therefore plausible that the observed retinal pigment clumping represents a 284 
visible manifestation of local Rab27a-associated melanosome transport 285 
dysfunction, and that other vesicle trafficking problems co-exist. Ultimately these 286 
result in RPE disease and death. Unlike choroidal melanocytes, the RPE 287 
melanosomes are fully mature at birth, and are incapable of renewal, perhaps 288 
explaining why the RPE is so sensitive to REP-1 dysfunction.9  289 
 290 
Following widespread pigmentary changes, well-defined regions of atrophy 291 
develop, most commonly in the post-equatorial region, just outside the vascular 292 
arcades. These changes advance centripetally whilst the far periphery seems to 293 
be relatively spared. It is possible that this stereotypical feature of disease may 294 
either relate to the underlying arrangement of lobular choroidal anatomy, 295 
regional differences in RPE metabolism or indeed both, and explain why these 296 
changes are not so readily seen in the anterior retina. A similar pattern of retinal 297 
degeneration occurs in gyrate atrophy (OMIM 258870) and dominant mutation 298 
of RPE65, but may also be observed in late-onset retinal degeneration (L-ORD, 299 
OMIM 605670), all conditions that are thought to affect the RPE.10  300 
 301 
Peri-papillary disease has been poorly described to date. In this series all 302 
patients, even the youngest showed significant para- and peri-papillary atrophy. 303 
Whilst objective analysis of the retinal nerve fibre layer in this region has been 304 
performed, detailed assessment of the surrounding outer retina changes has not 305 
been reported.11-13 It is unclear why patients with CHM have early peri-papillary 306 
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involvement, whilst in retinal disease associated with biallelic ABCA4 mutations 307 
this retinal region is spared. One possibility is that choroidal blood flow may 308 
influence the rate of progression, as degeneration in CHM appears to 309 
preferentially occur in loci where the choroid is at its thinnest.  310 
 311 
In addition to causing a progressive retinopathy, mutation of CHM could 312 
theoretically also result in anatomical changes present at birth or shortly 313 
thereafter. In keeping with this hypothesis, persistence of the inner retinal layers 314 
was identified in approximately half of the cases (15/27), a similar finding to 315 
that seen in patients with another disorder of hypomelanosis – albinism, where 316 
variable degrees of foveal hypoplasia are observed.14 In some cases however, 317 
very dense scans through fixation were not obtained, so it remains possible that 318 
a normal foveola exists but was just not captured. Usually however, the foveal pit 319 
is large enough to be identifiable on at least two normal density macula line 320 
scans, as such we feel that its absence is not due to technical factors. Again, in 321 
keeping with incomplete foveal maturation, changes in central foveal 322 
autofluorescence were also noted, perhaps indicating subtle alterations in the 323 
amount of luteal pigment within Henle layer, a finding otherwise unexpected in 324 
the earliest stages of many other retinal dystrophies. Lastly, macular hole 325 
formation is an extremely uncommon complication of inherited retinal disease, 326 
with only scattered single cases identified.15 Unusually, a recent report describes 327 
the prevalence of macular hole formation in patients with CHM at 10%, again 328 
hinting at a possible underlying developmental macular anomaly.16 Alternatively 329 
this may either relate to a high prevalence of pre-retinal glial cell proliferation in 330 
advanced disease resulting in mechanical traction from epiretinal membrane 331 
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tissue or the consequence of chronic cystic change. 332 
 333 
Another feature associated with chorioretinal atrophy is ORT.17 In our study ORT 334 
was notably absent from regions of established atrophy, and only found adjacent 335 
to healthy tissue, suggesting that the remaining (overhanging) photoreceptors 336 
may organise themselves around residual islands of RPE cells. Other signs of 337 
advanced atrophy, such as “ghost drusen” (highly reflective pyramidal 338 
structures), a common feature of advanced L-ORD (unpublished observation), 339 
are absent. Similarly, although late-stage retinal disease may also be complicated 340 
by choroidal neovascularization (CNVM), this is thought to be an uncommon 341 
feature of end-stage CHM. Cases of presumed CNVM, similar to that observed in 342 
patient 10 do exist, and have been reported by others.18 The true prevalence of 343 
CNVM will be hard to determine however, as generally only symptomatic 344 
patients are identified. 345 
 346 
This study provides a detailed description of the clinical, imaging and genetic 347 
findings present in a large cohort of paediatric patients with CHM. We propose 348 
that the observed widespread pigmentary changes are a visible consequence of 349 
Rab27a dysfunction, and highlight novel anatomical changes present both in the 350 
peri-papillary retina and inner retina at the fovea. In addition, we have presented 351 
SD-OCT data demonstrating a reduction in subfoveal choroidal thickness with 352 
disease progression, and a simultaneous increase in foveal retinal thickness, both 353 
of which occur whilst visual acuity is maintained. Deterioration in visual acuity is 354 
uncommon in CHM in childhood but when it does occur it is associated with a 355 
reduction in retinal thickness. The anatomical changes described herein were 356 
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evident even in the youngest patients, and hence must occur early in the disease 357 
course. We envisage that these objective imaging parameters will become useful 358 
tools for monitoring change, both in prospective natural history studies of CHM 359 
and in response to future treatments. 360 
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LEGENDS 413 
Figure 1: Colour fundus photography in patients with choroideraemia. (a) Early, 414 
fine, granular pigmentary changes in the central macula and around the vascular 415 
arcades, (b) larger pigment plaques in the temporal periphery. (c) Four years 416 
later the regions of pigmentary change have now evolved to atrophy, also 417 
involving the peripapillary retina (patient 4). Images (d, e) and (f, g) taken from 418 
patient 5 two years apart, highlighting progressive PPA. (h, i) Optos 419 
pseudocolour images from patient 7 highlighting well defined scalloped atrophy 420 
and pigment plaques with less well-defined anterior changes.  421 
 422 
Figure 2: Fundus autofluorescence images demonstrating the progression in 423 
peripapillary atrophy in patient 2 (a, b). Three distinct zones of autofluorescence 424 
are visible in patient 6 – complete absence, speckled and normal (c, d).  425 
 426 
Figure 3: Spectral domain optical coherence tomography in patients with 427 
choroideraemia. Approximately half of all eyes demonstrated persistence of the 428 
inner retinal layers (a, b). In regions immediately adjacent to atrophic retina, loss 429 
of retinal structure was associated with the presence of cystic spaces in either 430 
the outer or inner nuclear layers (c). Outer retinal tubulations were observed 431 
only in regions retaining small islands of retinal pigment epithelium, but never in 432 
areas of frank atrophy (d). Imaging the left eye of Patient 10 shows the presence 433 
of highly reflective subretinal material, suggestive of prior choroidal 434 
neovascularization (e). 435 
 436 
Table  1. Patient demographics 
 
 
RE = right eye, LE = left eye, VA = visual acuity, - = not performed 
 
 Age  
 
Refraction 
RE 
Refraction 
LE 
Mutation Follow 
up 
(years) 
 ΔVA 
(RE/LE) 
[decimal 
Snellen/ 
year]  
ΔRetinal 
thickness 
(RE/LE) 
[μm/month] 
ΔChoroid
al 
thickness 
(RE/LE) 
[μm/ 
month] 
ΔBAF 
area 
(RE/LE) 
[mm2/ 
month]  
1 13 n/a n/a Tyr42Ter 12.9 0, 0 6.3, -1.5 -9.5, -4.5 0.36, 0.25 
2 10 n/a n/a no testing 11.0 0, 0   - 
3 
16 
+0.75/-
0.25x90 
-0.50/-
0.25x55 p.Lys415AsnfsX4 
9..2 0, 0 2.3, 1.3 -13.6, -11 - 
4 
5 
n/a n/a c.G2931insA, 
p.Glu311fs 
9..6 0, 0 - - - 
5 
12 
-1.50/-
0.75x70 
-0.75/-
1.25x85 deletion exons 1-11 
9..2 0, 0 3.3, 6.6 -1.3, -0.3 3.15, 3.5 
6 
10 
-2.00/-
0.25x45 
-1.75/-
0.25x120 c.525_526delAG 
13.5 0, 0 -0.6, -7.4 0, -3.6 0.2, 0.6 
7 4 +2.50DS +2.50DS no testing 9.4 0, 0 11, 8.6 -23.3, -10 2.4, 5.35 
8 
9 
+2.50/-
0.50x90 
+1.75/-
0.50x70 whole gene deletion 
10.1 +0.33, 
+0.33 
6.5, 6.5 -10, 0 - 
9 
3 
+3.00/-
0.50x180 
+3.00DS 
no testing 
8.7 0, 0 9.5, 17.5 -36.5, -40 - 
10 
3 
+2.00/-
0.50x180 
+2.00/-
0.50x180 no testing 
12.0 0, 0 - - - 
11 
8 
+3.25/-
0.50x90 
+3.00/-
0.25x90 negative screen 
4.2 0, +0.33 - - - 
12 
9 
+2.50/0.25x
180 
+2.50DS 
no testing 
1.0  9.5, 17.5 - - 
13 
7 
+2.75/-
0.25x180 
+2.00/-
0.50x180 no testing 
6.7 +0.58, 
+0.58 
- -17.6, -21.5 - 
14 
12 
+2.75/-
0.50x50 
+2.75/-
0.50x140 
c.703-1_727delins 
TTAGA 
0.6 0, 0 - - - 
15 10 - - negative screen 6.6 0, 0 0.8, 1.5 -0.5, -1.3 - 
16 
15 
-0.75/-
1.75x10 
-0.25/-
2.00x170 c.831delC 
3.6 0, 0 3, 3.5 -4, -4 - 
17 
15 
-
1.75/+1.25x
95 
-
1.50/+1.50x
80 no testing 
1.0 0, 0 - - - 
18 
6 
+2.00/-
0.25x20 
+2.75/-
1.25x160 no testing 
Single 
visit 
- - - - 
19 
12 
+7.5/+1.75x
5 
+8.0/-
1.50x180 p.Asn360ThrfsX49 
3.9 0.14, 
0.16 
- - - 
20 – 
twin 
1 7 
+2.50/-
0.50x20 
+2.50/-
0.50x160 
 
5.6 0, 0 11.6, 8 0.3, 4.3 - 
21 – 
twin 
2 7 
+2.25DS +2.00DS 
negative screen in 
mother 
5.6 0, 0 2.6, 2.3 -3.3, -10.6 - 
22 
10 
+4.00/-
1.50x180 
+4.00/-
1.50x10 no testing 
4.0 0, 0 3.3, 2.3 -25.6, -15.6 - 
23 
14 
- - p.Arg253Ter not 
present in mother 
3.7 -0.33,  
-0.33 
- - - 
24 
7 
+4.00/-
0.25x180 
+4.00/0.50x
180 no testing 
3.7 -0.1, -0.1 -18, -24 -61, -35 - 
25 15 -0.75DCx20 0.50DCx160 c.282delT 1.0 0.50,0.24 - - - 
26 6 +2.25DS +2.50DS c.675dupG 1.25 0, 0 13, -6 -3, -4 - 
27 10 - - del intron 1-7  1.2 -0.1, -0.1 -6, -4 -44, -1 - 
28 7 +2.0DS +1.75DS pArg270Ter 1.25 0, -0.1 -16, -6 -17, -17 - 
29 
6 
+1.25/-
1.25x165 
0.75/-
1.50x7.5 c.1349+1delG 
1.5 0, 0 - - - 
Table
Table  1. Patient demographics 
 
 
RE = right eye, LE = left eye, VA = visual acuity, - = not performed 
 
 Age  
 
Refraction 
RE 
Refraction 
LE 
Mutation Follow 
up 
(years) 
 ΔVA 
(RE/LE) 
[decimal 
Snellen/ 
year]  
ΔRetinal 
thickness 
(RE/LE) 
[μm/month] 
ΔChoroid
al 
thickness 
(RE/LE) 
[μm/ 
month] 
ΔBAF 
area 
(RE/LE) 
[mm2/ 
month]  
1 13 n/a n/a Tyr42Ter 13 0, 0 6.3, -1.5 -9.5, -4.5 0.36, 0.25 
2 10 n/a n/a no testing 11 0, 0   - 
3 
16 
+0.75/-
0.25x90 
-0.50/-
0.25x55 p.Lys415AsnfsX4 
9 0, 0 2.3, 1.3 -13.6, -11 - 
4 
5 
n/a n/a c.G2931insA, 
p.Glu311fs 
10 0, 0 - - - 
5 
12 
-1.50/-
0.75x70 
-0.75/-
1.25x85 deletion exons 1-11 
9 0, 0 3.3, 6.6 -1.3, -0.3 3.15, 3.5 
6 
10 
-2.00/-
0.25x45 
-1.75/-
0.25x120 c.525_526delAG 
13 0, 0 -0.6, -7.4 0, -3.6 0.2, 0.6 
7 4 +2.50DS +2.50DS no testing 9 0, 0 11, 8.6 -23.3, -10 2.4, 5.35 
8 
9 
+2.50/-
0.50x90 
+1.75/-
0.50x70 whole gene deletion 
10 +0.33, 
+0.33 
6.5, 6.5 -10, 0 - 
9 
3 
+3.00/-
0.50x180 
+3.00DS 
no testing 
8 0, 0 9.5, 17.5 -36.5, -40 - 
10 
3 
+2.00/-
0.50x180 
+2.00/-
0.50x180 no testing 
12 0, 0 - - - 
11 
8 
+3.25/-
0.50x90 
+3.00/-
0.25x90 negative screen 
4 0, +0.33 - - - 
12 
9 
+2.50/0.25x
180 
+2.50DS 
no testing 
1  9.5, 17.5 - - 
13 
7 
+2.75/-
0.25x180 
+2.00/-
0.50x180 no testing 
7 +0.58, 
+0.58 
- -17.6, -21.5 - 
14 
12 
+2.75/-
0.50x50 
+2.75/-
0.50x140 
c.703-1_727delins 
TTAGA 
0.6 0, 0 - - - 
15 10 - - negative screen 7 0, 0 0.8, 1.5 -0.5, -1.3 - 
16 
15 
-0.75/-
1.75x10 
-0.25/-
2.00x170 c.831delC 
3 0, 0 3, 3.5 -4, -4 - 
17 
15 
-
1.75/+1.25x
95 
-
1.50/+1.50x
80 no testing 
1 0, 0 - - - 
18 
6 
+2.00/-
0.25x20 
+2.75/-
1.25x160 no testing 
0 - - - - 
19 
12 
+7.5/+1.75x
5 
+8.0/-
1.50x180 p.Asn360ThrfsX49 
4 0.14, 
0.16 
- - - 
20 – 
twin 
1 7 
+2.50/-
0.50x20 
+2.50/-
0.50x160 
 
6 0, 0 11.6, 8 0.3, 4.3 - 
21 – 
twin 
2 7 
+2.25DS +2.00DS 
negative screen in 
mother 
6 0, 0 2.6, 2.3 -3.3, -10.6 - 
22 
10 
+4.00/-
1.50x180 
+4.00/-
1.50x10 no testing 
4 0, 0 3.3, 2.3 -25.6, -15.6 - 
23 
14 
- - p.Arg253Ter not 
present in mother 
3 -0.33,  
-0.33 
- - - 
24 
7 
+4.00/-
0.25x180 
+4.00/0.50x
180 no testing 
3 -0.1, -0.1 -18, -24 -61, -35 - 
25 15 -0.75DCx20 0.50DCx160 c.282delT 0 0.50,0.24 - - - 
26 6 +2.25DS +2.50DS c.675dupG 1 0, 0 13, -6 -3, -4 - 
27 10 - - del intron 1-7  1 -0.1, -0.1 -6, -4 -44, -1 - 
28 7 +2.0DS +1.75DS pArg270Ter 1 0, -0.1 -16, -6 -17, -17 - 
29 
6 
+1.25/-
1.25x165 
0.75/-
1.50x7.5 c.1349+1delG 
1 0, 0 - - - 
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